Background
==========

Colorectal cancer (CRC) is a common digestive tumor; the incidence of CRC is just lower than gastric and esophageal cancer. More than one million new cases of CRC were diagnosed globally each year \[[@b1-medscimonit-21-1611]\]. CRC is becoming a very urgent public health concern, especially in the developed countries. In USA, the incidence rate and mortality rate of CRC ranked third among all tumors in both men and women \[[@b2-medscimonit-21-1611]\]. Body mass index, height, smoking status, and alcohol use have been reported to be associated with CRC risk \[[@b3-medscimonit-21-1611]\]. However, the pathogenesis of CRC is still uncertain. Identification of related genetic variants could elucidate mechanisms underlying this disease.

Peroxisome proliferators-activated receptors (PPAR), which have PPARα, PPARβ/δ and PPARγ, are members of the nuclear receptor superfamily of ligand-activated transcription factors \[[@b4-medscimonit-21-1611]\]. Due to its association with many human cancers such as colon, thyroid, breast, and prostate, PPARγ has been suggested to be an attractive target for cancer therapy \[[@b4-medscimonit-21-1611]\]. Although the PPARγ nuclear receptor pathway was involved in cancer development, it might appear to have both oncogenic and tumor suppressor functions. Sarraf et al. showed that ligand activation of PPARγ in colon cancer cells could cause a considerable reduction in linear and clonogenic growth, increase expression of carcinoembryonic antigen, and the reversal of many gene expression events specifically associated with colon cancer \[[@b5-medscimonit-21-1611]\]. However, Saez et al. suggested that PPARγ activation may provide a molecular link between a high-fat diet and increased risk of CRC \[[@b6-medscimonit-21-1611]\].

A common polymorphism in the PPARγ, CCA®GCA, causing a Pro®Ala substitution at codon 12 (Pro12Ala), has been reported. The Pro12Ala polymorphism has been suggested to be associated with decreased receptor activity, lower body mass index, and improved insulin sensitivity \[[@b7-medscimonit-21-1611]\]. The Pro®Ala change might cause a conformational change in the PPARγ protein, and thus affect its activity. Several studies have reported the association between PPARγ Pro12Ala polymorphism and CRC risk \[[@b8-medscimonit-21-1611]--[@b22-medscimonit-21-1611]\]. However, the results were still equivocal. Recently, a meta-analysis with nine studies found that this polymorphism was not associated with CRC risk \[[@b23-medscimonit-21-1611]\]. However, six case-control studies were published and not all studies supported that result. Therefore, we performed a meta-analysis of all eligible studies to evaluate the association between PPARγ Pro12Ala polymorphism and CRC risk.

Material and Methods
====================

Material
--------

We conducted a literature search using PubMed, EMBASE, and Cochran databases. The following terms were used: "colorectal neoplasms" or "colorectal cancer") and ("PPARγ" or "peroxisome proliferators-activated receptor γ"). The last search was updated on December, 2014. All searched studies were retrieved and only published studies with full-text articles were included. In duplicate samples, only the largest study was used in this research.

Inclusion/exclusion criteria
----------------------------

The inclusion criteria was as follows: (1) a case-control study or a cohort study; (2) the study evaluated the association between PPARγ Pro12Ala polymorphism and CRC risk; (3) the PPARγ Pro12Ala genotypes were provided.

The exclusion criteria were as follows: (1) animal studies; (2) not relevant to CRC or PPARγ; (3) reviews or abstracts; (4) not offer enough data.

Data extraction
---------------

Two authors extracted the following data: first author, year, race, sample size, and genotype distribution. The disagreements were resolved by consensus.

Statistical analysis
--------------------

Statistical analysis was all conducted using Stata software 11.0 (StataCorp, College Station, Texas, USA). HWE test in healthy control group was conducted using χ^2^ test. Odds ratio (OR) with a 95% confidence interval (CI) was presented for dichotomous data, and significance level was 0.05. Dominant model, recessive model, and additive model were used in this meta-analysis. *Q*-statistic and *I^2^*-statistic were used to measure statistical heterogeneity and significance level was 0.10. Effect model selection was on the basis of heterogeneity test. Fixed-effect models was selected when no significant heterogeneity, otherwise we used the random-effects model. Subgroup analyses were carried out based on race and cancer site. To evaluate the reliability of the results, one-way sensitivity analyses and cumulative meta-analysis were performed. Publication bias was investigated by the method of Egger's test. The two-sided *P*\<0.05 was considered statistically significant.

Results
=======

Eligible studies
----------------

[Figure 1](#f1-medscimonit-21-1611){ref-type="fig"} shows the study selection procedure. Based on the inclusion and exclusion criteria, 15 studies including 13575 cases and 17085 controls were included in our meta-analysis. Only three studies were performed in Asian populations, while other studies were performed in Caucasian populations. The characteristics of the included studies are listed in [Table 1](#t1-medscimonit-21-1611){ref-type="table"}.

Quantitative synthesis
----------------------

Result of this meta-analysis suggest that PPARγ Pro12Ala polymorphism was significantly associated with a reduced risk of CRC in dominant genetic model (OR=0.90; 95% CI 0.83--0.98; *P*=0.01; [Figure 2](#f2-medscimonit-21-1611){ref-type="fig"}). No significant association was found between PPARγ Pro12Ala polymorphism and CRC risk in Asians (OR=0.80; 95% CI 0.60--1.09; *P*=0.15). However, PPARγ Pro12Ala polymorphism was significantly associated with a reduced risk of CRC in Caucasians (OR=0.91; 95% CI 0.83--0.99; *P*=0.03). When stratified analysis was performed by CRC site, no positive association was found between PPARγ Pro12Ala polymorphism and rectal cancer (OR=0.95; 95% CI 0.74--1.22; *P*=0.71). However, a reduced risk of colon cancer was observed (OR=0.85; 95% CI 0.76--0.94; *P*=0.002). Results of other genetic models are listed in [Table 2](#t2-medscimonit-21-1611){ref-type="table"}.

To evaluate the reliability of the results, we conducted cumulative meta-analysis by pooling the data, and each time one study was added. The results showed that the pooled ORs tended to be stable ([Figure 3](#f3-medscimonit-21-1611){ref-type="fig"}). We also performed the one-way sensitivity analysis by omitting studies one at a time. We found that any single study did not influence the pooled OR, suggesting that the results of this meta-analysis were robust ([Figure 4](#f4-medscimonit-21-1611){ref-type="fig"}). Moreover, no significant publication bias was found by funnel plot ([Figure 5](#f5-medscimonit-21-1611){ref-type="fig"}) and Egger's test (*P*=0.12)

Discussion
==========

PPARγ Pro12Ala polymorphism has been reported to be associated with breast cancer, gastric cancer, and inflammatory bowel disease \[[@b24-medscimonit-21-1611]--[@b26-medscimonit-21-1611]\]. Lu et al. suggested that PPARγ Pro12Ala polymorphism was not associated with CRC risk \[[@b23-medscimonit-21-1611]\]. However, a previous meta-analysis found that PPARγ Pro12Ala polymorphism might be a protective factor for CRC \[[@b26-medscimonit-21-1611]\]. Thus, we did this update meta-analysis to find the association between PPARγ Pro12Ala polymorphism and CRC risk. We found that PPARγ Pro12Ala polymorphism was significant associated with CRC risk, suggesting that PPARγ Ala allele carriers had reduced CRC risk compared to PPARγ Pro allele carriers. Furthermore, we found that this effect was only existed in Caucasians but not in Asians, suggesting a possible influence among different genetic backgrounds and environmental exposures, but these were only studies with Asians. More studies with Asians are needed to further investigate the association between PPARγ Pro12Ala polymorphism and CRC risk. Results from this meta-analysis found that PPARγ Pro12Ala polymorphism was only associated with colon cancer. No significant association was found between PPARγ Pro12Ala polymorphism and rectal cancer. It has been suggested that PPARγ activity was higher in the distal colon \[[@b27-medscimonit-21-1611]\]; it is possible that the Ala/Ala+Pro/Ala genotypes had the greatest effect in the segment of the colon with the least PPARγ activity \[[@b28-medscimonit-21-1611]\].

Ligands for the PPARγ have proven to be effective in preclinical models of CRC. Tanaka and coworkers indicated that administration of the PPARγ ligand troglitazone significantly reduces the number of aberrant crypt foci (ACF) lesions \[[@b29-medscimonit-21-1611]\]. Aires et al. found that the combination of resveratrol with a PPARγ agonist could be a promising pharmacological approach for treatment of CRC \[[@b30-medscimonit-21-1611]\]. Thus, PPARγ agonists combined with other chemotherapy drugs or other targeted therapies are worth pursuing in the treatment of CRC \[[@b31-medscimonit-21-1611]--[@b36-medscimonit-21-1611]\].

There were some limitations in this meta-analysis. First, the number of included studies was moderate. Therefore, the results could be influenced by random error. Second, CRC is a multifactorial disease, but the interactions among gene-environment and gene-gene were not considered in this meta-analysis. Third, other factors such as gender or diet habit may participate in the progression of CRC. However, we did not conduct subgroup analysis by these factors due to limited data.

Conclusions
===========

In summary, this study suggested that PPARγ Pro12Ala polymorphism was a protective factor of CRC.
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###### 

Characteristics of case-control studies included in this meta-analysis of the association between the PPARγ Pro12Ala polymorphism and CRC risk.

  First author     Year   Ethnicity   No. of eligible subjects   Case   Control                
  ---------------- ------ ----------- -------------------------- ------ --------- ------ ----- ------
  Landi            2003   Caucasian   360                        309    49        311    66    243
  Jiang            2005   Asian       303                        293    63        240    63    230
  McGreavey        2005   Caucasian   455                        513    89        366    110   403
  Murtaugh         2005   Caucasian   2371                       2972   531       1840   689   2283
  Koh              2006   Asian       362                        1164   17        345    89    1075
  Kuriki           2006   Asian       127                        238    7         120    17    221
  Slattery         2006   Caucasian   2371                       2972   531       1840   689   2283
  Theodoropoulos   2006   Caucasian   222                        200    58        164    82    118
  Vogel            2007   Caucasian   355                        753    103       252    203   550
  Küry             2008   Caucasian   811                        811    168       633    178   643
  Slattery         2009   Caucasian   1577                       1971   343       1234   478   1493
  Hawken           2010   Caucasian   1133                       1125   239       886    290   843
  Abulí            2011   Caucasian   515                        502    89        426    83    419
  Crous-Bou        2012   Caucasian   812                        1479   102       710    172   1307
  Sainz            2012   Caucasian   1801                       1783   447       1354   449   1334

###### 

Meta-analysis of association between the PPARγ Pro12Ala polymorphism and CRC risk.

                    Pooled OR (95% CI)   *P*~OR~   *I^2^*   *P*~Q~
  ----------------- -------------------- --------- -------- --------
  Dominant model                                            
   All              0.90 (0.83--0.98)    0.01      42%      0.04
   Asian            0.80 (0.60--1.09)    0.15      1%       0.37
   Caucasian        0.91 (0.83--0.99)    0.03      49%      0.03
   Rectal           0.95 (0.74--1.22)    0.71      56%      0.06
   Colon            0.85 (0.76--0.94)    0.002     0%       0.45
  Recessive model                                           
   All              0.87 (0.79--0.94)    0.001     32%      0.35
   Asian            0.94 (0.73--1.21)    0.64      11%      0.34
   Caucasian        0.87 (0.78--0.97)    0.02      0%       0.74
   Rectal           0.87 (0.76--1.02)    0.07      61%      0.01
   Colon            0.86 (0.74--0.99)    0.04      39%      0.37
  Additive model                                            
   All              0.84 (0.72--0.97)    0.03      50%      0.03
   Asian            0.82 (0.62--1.12)    0.34      21%      0.22
   Caucasian        0.89 (0.80--0.96)    0.01      34%      0.33
   Rectal           0.93 (0.72--1.20)    0.65      43%      0.08
   Colon            0.83 (0.74--0.92)    0.001     14%      0.56

*P*~OR~ and *P*~Q~ refer to the significance levels of the odds ratio and Q-test of heterogeneity, respectively.
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